Skip to main content

Market Overview

EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots

EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots
  • The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE: JNJ) and AstraZeneca plc (NASDAQ: AZN) to reflect several newly detected side effects.
  • The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalized the updates to the product information of J&J’s (JNJ) single-dose shot to indicate “swollen lymph nodes, unusual or decreased feeling in the skin, tinnitus, diarrhea, and vomiting,” as potential side effects.
  • EMA said that for AstraZeneca’s vaccine, the product information would be updated to reflect Guillain-Barré syndrome (GBS) as a side effect.
  • Related Content: European Medicine Agency Lists Guillain-Barré Syndrome As Rare Side Effect For JNJ COVID-19 Vaccine.
  • Price Action: JNJ shares are down 0.20% at $172 during the market session on the last check Wednesday.
  • Photo by Johaehn from Pixabay

Related Articles (AZN + JNJ)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 Coronavirus COVID-19 Vaccine European Medicines AgencyNews FDA Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at